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Abstract 
Cardiovascular disease is the number one cause of death in the United States. 
Approximately 8 million people in the United States suffered from a myocardial 
infarction last year. This Major Qualifying Project looks to automate the process of 
isolating cardiogenic cells.  These cardiogenic cells provide an opportunity to help regain 
lost heart function after a myocardial infarction.  This was accomplished through the 
design of an automated trituration system for isolation of cardiogenic cells.   
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Introduction 
 
Cardiovascular disease is the number one cause of death in the United States 
today.  According to the 2007 American Heart Association Statistical Update, 
approximately 8 million people in the United States suffered from a myocardial infarction 
(MI) in one year and this statistic is rising (Committee, 2007).  MI occurs when the blood 
supply to a portion of the heart is interrupted.  This interruption is caused by a blockage 
or buildup of plaque in a coronary artery.  The affected area of the heart loses its blood 
and nutrient supply causing the heart tissue to die.  The heart cannot effectively perform 
its required functions for the body.  A method is needed to repair or replace the damaged 
heart muscle in order for the heart to regain normal function.  
It is estimated that over one billion cells die when a major MI occurs, which 
results is loss of heart function or even heart failure (Murry, 2006).  This death of cardiac 
tissue is detrimental to the function of the heart because cardiac myocytes, the cells that 
make up the myocardial tissue, have no or limited ability to regenerate after damage from 
a MI.  One treatment method for cardiovascular disease involves the delivery of 
cardiogenic stem cells to the heart.  In order to acquire cardiogenic cells, the process that 
is currently used produces spheroid bodies, which then generate cells expressing 
myocardial markers that can be isolated.  Once these cells are isolated, they can then be 
sorted into cardiogenic and non-cardiogenic cells.  These viable, cardiogenic cells can 
then be used to treat cardiovascular damage.  
 The objective of this Major Qualifying Project is to develop a method for 
isolation of cardiogenic cells produced through spheroid body formation.  The method 
must allow for maximized cell isolation in a completely sterile environment while 
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ensuring that the cells retain their cardiogenic potential.  The deliverables will include a 
paper detailing the process, a working prototype of the device and methods used.
13 
 
Literature Review 
Significance 
 
Cardiovascular disease is the number one cause of death in the United States 
today.  According to the 2007 American Heart Association Statistical Update, 
approximately 8 million people in the United States suffered from a myocardial infarction 
(MI) in one year and this statistic is rising (Committee, 2007).  MI occurs when the blood 
supply to a portion of the heart is interrupted.  This interruption is caused by a blockage 
of a coronary artery.  The affected area of the heart loses its blood supply.  One of the 
most detrimental consequences of this blockage is that oxygen cannot be delivered to this 
area of the heart, potentially causing this part of the heart tissue to die due to lack of 
oxygen.  The function of the heart is to pump blood throughout the body.  Blood 
circulates oxygen, nutrients, and removes waste. 
 The heart cannot effectively perform its required function of circulating blood 
throughout the body when a large part of the heart muscle has died as a result of a MI.  A 
method is needed to repair or replace the damaged heart muscle in order for the heart to 
regain normal function. 
It is currently believed that after a MI, cardiac myocytes are unable to regenerate.  
In order to help the heart regain its normal function, regeneration or replacement of the 
damaged area is needed.  One method that is being researched is isolating stem cells and 
delivering them to the affected area for cardiac repair (Stamm, 2003).  These cells can be 
delivered through a variety of methods including tissue scaffolds, injection of cardiac 
myocytes directly into the heart, or into the blood supply.  Ideally these cells will 
proliferate and replace the damaged tissue.  
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The Heart 
 
 The heart supplies the body with blood, oxygen and nutrients.  It is located 
between the lungs, behind and to the left of the sternum in the chest.  The entire organ is 
surrounded by a two layered sac called the pericardium.   
The heart is about the size of a fist, and is comprised of four chambers.  The two 
smaller, upper chambers are called the atria, while the larger, lower chambers are called 
the ventricles.  The left and right sides of the heart are separated by a structure called the 
septum.  The left ventricle is the largest, most muscular chamber because this chamber is 
responsible for pumping blood from the heart to the entire body (Marieb, 2007).  The 
blood flows in a specific path.  The blood enters the heart from the body via the superior 
and inferior vena cava into the right atrium.  The blood then flows through the tricuspid 
valve into the right ventricle.  From the right ventricle the blood is pumped through the 
pulmonary valve to the lungs via the pulmonary arteries.  An exchange of gas occurs at 
the capillary level in the lungs as CO2 is exchanged for O2.  The now oxygen rich blood 
is carried back to the heart via the pulmonary veins and into the left atrium.  From the left 
atrium, the blood flows through the bicuspid valve into the left ventricle (Marieb, 2007) .  
The left ventricle then pumps the oxygen enriched blood to the body via the aorta.  The 
blood and nutrients are carried through the body via the cardiovascular system which 
consists of the heart and its network of arteries, arterioles, capillaries, venuoles and veins 
(Marieb, 2007).  
 The heart contractions are controlled by electrical impulses.  The electrical signal 
starts at the sinoatrial node (SA node), that is located near the top of the right atrium.  The 
electrical impulse travels from the SA node to the atria via the muscle fibers, made up of 
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cardiac myocytes, causing the contraction to occur and blood to be pumped.  These 
impulses come at a constant rate unless the body’s demands change due to stress, 
physical needs or hormonal factors (Marieb, 2007).  The impulses then travel through the 
fibers to the atrioventricular node (AV node), which causes the ventricles to contract.  
The heart beat is actually a two stage process.  The first stage occurs when the SA node 
triggers the atria to contract and force blood to the ventricles.  Once the ventricles are 
full, the AV node fires and the ventricles contract and pump the blood to the lungs and 
body.   
 The heart supplies itself with blood and nutrients, as well.  The heart has its own 
vascular network called the coronary arteries.  Two arteries stem off of the aorta and 
break into smaller vasculatures and supply the entire heart with blood and nutrients.  The 
right coronary artery mostly supplies the right side of the heart, and the left coronary 
artery supplies the left side.  When one of these vasculatures narrows or has a plaque 
buildup, blood flow is lessened.  When there is a complete blockage and all oxygen and 
nutrients are cut off to a section of the heart an acute myocardial infarction (MI) or heart 
attack can occur (Gray, 2000).  The oxygen shortage or ischemia causes part of the heart 
tissue to die.  In fact, it is estimated that over one billion cells die when an MI occurs 
(Murry, 2006).  This death of cardiac tissue is detrimental to the function of the heart 
because cardiac myocytes, the cells that make up the myocardial tissue, have no or 
limited ability to regenerate after damage from an MI.  
  Cardiac Myocyte 
 
Cardiac myocytes are the cells that form cardiac muscle, which is responsible for 
pumping blood through the heart through involuntary contractions.  These cells are 
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affected by an MI.  Cardiac muscle cells are striated muscle cells which differ from 
smooth muscle cells which line the gastrointestinal tract or skeletal muscle cells which 
make up the quadricep.  The physical attributes of cardiac myocytes are marked by the 
cross striations that are formed by alternating layers of protein filaments in the sarcomere.  
The sarcomere is the basic unit of a muscle cross-striated myofibril (Marieb, 2007).  The 
myofibril is the organelle in the cell that contains bundles of actomyosin filaments that 
are attached at either end of the cell.  The main structural proteins of the myocyte are 
myosin and actin. The actin filaments are thin and the myosin filaments are thicker.  The 
actin protein aids in muscle contractions and myosin produces the contractile force that 
drives the contractions (Marieb, 2007).  
 Specialized pacemaker cells at the entrance of the right atrium designated the 
sinoatrial (SA) node, pace the contractions of the heart.  These nodal cells are different 
from other types of cells in the body due to their myogenic affinity (Gray, 2000).  This 
means that the cell uses self-excitable stimulating contractions to mediate the heart 
pumping without aid from an electrical impulse coming from the central nervous system. 
These action potentials are then conducted throughout the rest of the myocardium causing 
the muscle to contract in a rhythmic synchronic fashion.  These cells are stimulated by 
the autonomic nervous system and will continue pacing each other unless the contraction 
is disrupted, for example, by a MI. The myocytes are connected together by intercalated 
discs which allow for propagation of theses action potentials across the cell membranes 
by the use of different types of junctions. These electrical pulses are created by the flow 
of ions from myocyte to myocyte called action potentials (Gray, 2000). 
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Intercalated discs are double membranes separating each myocyte within the 
cardiac fibers.  Within the discs, gap junctions aid in the passing of impulses from cell to 
cell. These junctions allow for the action potentials to extend through the cardiac 
myocytes by the passing of ions through these channels (Gray, 2000).  
Cardiac myocytes are critical to heart function.  These cells make up cardiac 
muscle and allow the heart to pump blood and nutrients to the entire body.  A working 
heart sustains life. 
Stem Cells  
 
In order to repair damage to the heart that results from a MI and heart disease, 
researchers and scientists are narrowing the focus in on stem cells as a solution.  Human 
mesenchymal stem cells (hMSCs) are multipotent cells and are present in adult bone 
marrow.  These cells can be obtained in large quantities and can be cultured without 
losing the ability to differentiate into different cell types.  They can be frozen for long 
periods of time, thawed out and still display normal cell behavior.  They also have the 
ability to take up introduced genes (Asahara, 2000).  As
 
undifferentiated cells, they have 
the potential to differentiate into the cells that make up bone, cartilage,
 
fat, tendon, 
muscle, and marrow.  HMSCs are a prime example of cells that can be isolated, expanded 
in culture,
 
and then characterized both in vitro and in vivo (Pittenger, 1999).  If hMSCs 
can be manipulated into cardiogenic cells and form cardiac myocytes, the possibility of 
someday curing heart disease could be one step closer in becoming a reality.  Hundreds 
of studies involving stem cells, more specifically mesenchymal stem cells, have been 
conducted in order to repair damaged heart tissue.  Along with these attempts to 
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manipulate the stem cells into cardiac myocytes, myogenic differentiation and different 
methods of insertion have been tested as well (Gang, 2004).  
 The methods used to stimulate myogenic differentiation in hMSCs vary.  One 
method used involves the implantation of hMSCs directly into the heart and observing 
whether or not the cells differentiate.  In a study conducted by Toma and colleagues, 
bone marrow aspirate was taken from the Iliac Crest of human volunteers (Toma, 2002). 
The stem cells were isolated, labeled with lacZ and 500,000 to 1 million were injected 
into the left ventricle of CB17 SCID/beige adult mice.  The mice were observed for 
several days.  After 4 days, the cells did not express any myogenic markers, and many of 
the cells did not survive after 1 week’s time.  However, over time the cells began to 
resemble cardiomyocytes.  The study reveals that the cells displayed evidence of desmin, 
ß-myosin heavy
 
chain, -actinin, cardiac troponin T, and phospholamban at levels
 
comparable to those of the host cardiomyocytes, and that sarcomeric organization
 
of the 
contractile proteins was observed.  These are all components of normal cardiac myocytes.  
The study concludes by suggesting that these cells may be used in the future for 
cardiomyoplasty (Toma, 2002).  
 In a study entitled, Autologous bone-marrow stem-cell transplantation for 
myocardial regeneration, tests were completed using the direct injection technique in six 
human patients (Stamm, 2003). All of these patients had sustained a myocardial 
infarction and undergone coronary artery bypass grafting (CABG).  The surgeons 
injected up to 1.5×10
6
 autologous AC133+ bone-marrow cells into the infarct border 
zone in each patient.  Three to nine months after the surgery, all the patients were alive 
and doing well.  Global left-ventricular function had enhanced in four of the patients, and 
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infarct tissue perfusion had improved dramatically in five of the patients.  The study 
concludes by suggesting that ―implantation of AC133+ stem cells to the heart is safe and 
might induce angiogenesis, thus improving perfusion of the infarcted myocardium 
(Stamm, 2003).‖  
 The overall goal in the implantation and experimentation of mesenchymal stem 
cells is to manipulate them in such a way that they will express cardiogenic markers.  The 
cells can then be implanted into the heart in various ways in order to repair damaged 
heart tissue.  In order for this step to be possible, a method for isolation of the cells after 
differentiation is needed. 
Cardiogenic Cells 
 
Cardiogenic cells are cells that express certain cardiogenic markers.  These 
cardiogenic markers include the following; sarcomeric α-actinin, α-myosin heavy chain, 
cardiotin, and atrial natriuretic peptide (ANP).  Cardiogenic markers are expressed in 
cardiac cells, such as cardiac myocytes, as well as cardiogenic cells.  These markers show 
that the cells are either cardiac cells or that they are beginning to differentiate into cardiac 
cells.  One possible use of cardiogenic cells is for transplantation into damaged heart 
tissue.  It has been show that cardiac stems cells exist in normal heart tissue.  This gives 
hope that the use of cardiogenic cells to replace damaged tissue may be an effective 
method to regenerate normal heart function (Beltrami, 2003).   
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Isolation Methods 
 
Currently there are a variety of ways to isolate cells.  The variety of isolation 
techniques varies depending on what types of cells are being isolated and how the cells 
are going to be used.  In a variety of articles researched, trypsin is used to separate the 
growing cells from the culture plate.  This is the first step in the process of isolating the 
cardiogenic cells from the non- cardiogenic cells. Once the stem cells have been 
trypsinized they can undergo further preparation for storage and use at a later date 
(Techawattanawisal, 2007).   
When the hMSCs are grown according to our specific lab procedures they form a 
spheroid.  This spheroid is a densely packed clump of cells.  Cardiogenic cells are 
believed to come off of the spheroid and move outward (Potapova, submitted).  These 
free cells need to be separated from the spheroid.  It is also desirable to be able to break 
up the spheroid itself so that these cells can be tested for cardiogenic markers.  This 
separation process can be executed by pipetting the spheroids repeatedly.  
Techawattanawisal, et al. suggests pipetting cell clumps repeatedly approximately 150 
times to obtain single cell suspension (Techawattanawisal, 2007).  The pipetting or 
trituration of cells causes the cells to experience shear stress and break apart from each 
other.  This added shear stress can induce cell membrane rupture leading to cell death.  
This is why it is important to pipette the cells for the empirically determined amount of 
time.  Once the cells are isolated from one another they can then be separated 
individually based on certain characteristics.   
Individual cells can be assayed to see if they express certain cardiogenic markers.  
One method to determine which cells express certain characteristics is flow cytometry.  
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Flow cytometry is a process where single cells suspended in a fluid pass through a beam 
of light and scatter the light in different patterns.  Fluorescent chemicals attached to the 
cells may be excited into emitting light at a lower frequency than the light source.  This 
allows the user to determine how many cells express certain characteristics. 
Fluorescence-activated cell sorting (FACS) is a method that uses flow cytometry to 
determine which cells display certain characteristics and then sort these cells out from the 
rest of the cells that do not express these characteristics.  Cells are separated according to 
different factors including cell surface antigens, enzymatic activity, proteins, and 
membrane potential.  Specific antibodies can be used to bind to antigens on target cells, 
making them easy to separate (Fu, 1999).  
This method has been proven to be effective in isolation of adipose tissue-derived 
stem cells (ASCs) (Yamamoto, 2007).  This technique has worked for stem cells derived 
from adipose tissue, it therefore warrants investigation to determine if this technique 
would also work for hMSCs.  Flow cytometry may turn out to be an effective method to 
sort cardiogenic cells from non-cardiogenic cells.   
Some cardiac markers that these hMSCs expressed included the following as 
stated in an article by Gaudette’s Laboratory.   
The cells spreading from the spheroids expressed cardiac specific proteins, 
including sarcomeric actinin, cardiotin, and atrial natriuretic peptide, and 
the cell cycle marker cyclin D1. They also express a calcium current 
similar in amplitude to that of ventricular myocytes (Potapova, submitted).  
 
This means that the cardiogenic cells express certain specific traits such as sarcomeric 
actinin, cardiotin, and atrial natriuretic peptide.  These unique markers could be used in 
FACS to separate the cells displaying these cardiogenic traits versus cells not exhibiting 
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cardiogenic traits.  This would allow the cells to be separated and the cardiogenic cells to 
be used in treatment of post myocardially infarcted hearts.       
 
Conclusion 
 
The heart is a complex organ that is needed in order to sustain human life.  When 
damaged, the chance of survival decreases significantly.  With an advanced knowledge of 
the heart, stem cells and isolation methods, scientists are in search of a method to repair 
damaged heart tissue. The initial steps in this search require a method for isolation of the 
cardiogenic cells in vitro after differentiation.  
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Project Approach 
 
Hypothesis  
 
The isolation of cells from a spheroid body containing hMSCs will yield viable, 
cardiogenic cells. 
Assumptions  
  
A major assumption of this project is that the spheroid bodies contain cardiogenic 
cells that are able to be isolated and maintain their viability.  
The other assumptions of our project are the number of cells that will be viable 
and cardiogenic after the process.  The first is that 50% of the original amount of cells 
will have cardogenic potential, the next is that 50% or greater single cells isolated from 
spheroid bodies, the next is that 80% or greater pure population of sorted cardiogenic 
cells and finally that there will be 80% or greater cell viability of the sorted cardiogenic 
cells.  The final assumption of this project is that starting with approximately 12,500 
hMSCs in the spheroid body will theoretically yield at least 2000 viable, cardiogenic 
single cells. 
Goal 
 
Our team goal is to develop a device that will effectively isolate cardiogenic cells 
formed from a spheroid body.  
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Design 
 
Initial Client Statement 
 
The initial client statement is to develop a method to effectively isolate single 
cardiogenic cells from a spheroid body.  One treatment method for cardiovascular disease 
involves the delivery of cardiogenic stem cells to the heart.  The process that is currently 
used to grow these cardiogenic cells leaves them in a spheroid body that needs to be 
broken up into single cells.  Once the cells are isolated they can then be sorted into 
cardiogenic and non-cardiogenic cells and then can be delivered to the heart to potentially 
treat cardiovascular disease in the future.  
Revised Problem Statement 
 
 The objective of this Major Qualifying Project is to develop a method for 
isolation of cardiogenic cells produced through spheroid body formation.  The method 
must allow for maximized cell isolation in a completely sterile environment while 
allowing the cells to retain their cardiogenic potential.  The design must follow the Good 
Manufacturing Process and scalability is desired.  The deliverables will include a paper 
detailing the process, a working prototype of the device and methods used.   
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Objectives 
Defining Objectives 
 
One of the main objectives of this design project was to isolate cardiogenic cells 
from a spheroid body.  The design of this device/method is based on separating cells in 
the most effective manner possible.  The cells must first be freed from the plate that they 
are cultured on with trypsin.  After this the spheroid body must be broken up into single 
cells.  This is accomplished by pipetting the spheroid body.    
After the spheroid body cells are isolated into single cells, the cardiogenic cells 
must be sorted from the non-cardiogenic cells.  Once the cardiogenic cells are separated 
from the other cells they can be used to treat a post MI heart.  These cardiogenic cells can 
be delivered to the infarcted area of the heart and regenerate cardiac muscle.   
The cells being cultured grow within a spheroid body.  As they grow, some of 
these cells separate from the spheroid body and move outward.  Some of these cells have 
already been proven to express cardiogenic markers (Rosen, 2007).  The cells within the 
spheroid body itself have not been studied to see if they express cardiogenic markers.  
For the purposed of this project, it has been assumed that these cells will also display 
cardiogenic markers.  
 A reliable device will work when it is operated properly.  It is important that each 
time the device is operated it completes the operation and there are no setbacks.  This will 
allow the user to maximize his/her time and maximize the usage of the device.  The 
device will be considered reliable if it has few moving parts and operates every time the 
operator wants. 
A durable device is essential.  If the device is always breaking, then the usefulness 
of the device decreases.  A durable device will not have any unexpected breakages if the 
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maintenance plan is followed.  This allows the user to operate the device whenever it is 
necessary without any unforeseen problems.  The device is considered durable if it has 
few moving parts, is constructed soundly by using proper connecting parts, and will 
remain unaffected by an occasional bump. 
Repeatable results are important to any scientific device.  It is required that a 
device produce repeatable results so that the data has statistical significance.  If the 
device continuously generates different outputs from the same inputs then it is of no real 
scientific use.  The device will be considered to produce repeatable results if it has an 
automated process which has few moving parts that could possible fail. 
The device should be efficient.  Cost and time need to be taken into consideration.  
It takes a significant amount of time to grow the hMSCs to the stage where they begin to 
display cardiogenic markers.  The process is also expensive.  For these reasons it is most 
desirable that the process be efficient.  This means that the device will deliver an output 
of 80%+ cardiogenic cells from the total number of cardiogenic cells put in.   
It is important that the device is easy to use.   If every time a user, especially a 
new user, operates the device they are confused and have many unclear options to choose 
from the device will not be considered easy to use.   It is important that the device is 
simple to operate so that the correct process can be carried out every time.  By carrying 
out the same process, then the same results will be obtained.  This is important so that the 
data collected can have statistical significance.  The device will be considered easy to use 
if it has only a few obvious choices for operation and is automated. 
The device should be automated throughout the whole process.   By having the 
device be automated, there is less variability from user to user.  This allows a variety of 
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different people to use the device and obtain the same results.  An automated device also 
makes it so that the user does not have to go through intense training.  The user is also 
less likely to do something incorrectly that would lead to the device breaking or a 
variation in the results.  An automated device will also save time because a person does 
not have to carry out all of the processes manually.   
 The device should be easy to clean and sterilize.  If the device is easy to clean 
then the cleaning process will take less time and the user is more likely to clean the 
device regularly.  The device will be considered easy to clean if all parts are disposable, 
can be autoclaved, or can be wiped down with disinfectant easily.     
 It is desirable that the device complete its functions in a short amount of time.  If 
this happens, then the rest of the process can continue without a hold up at the isolation/ 
separation step.  The device will be considered timely if it completes its functions in a 
few hours.   
The device must meet safety requirements.  The device must meet these safety 
requirements so that it can be brought to market.  It must also meet safety requirements 
so that it does not injure the user or anyone who is near it.  If the device injures the 
operator or other support staff that come in contact with it, it will not be accepted by the 
client.  It is also unethical to create a device that the designer knows is not safe and can 
harm the user.  The device will be considered to meet safety requirements if all the 
moving parts are enclosed, there are no sharp edges, and it meets International 
Organization for Standardization (ISO) requirements.  However, the device will be used 
in a laboratory setting for research purposes only and, therefore, is not considered a 
medical device by the Food and Drug Administration (FDA). 
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The outcome of this project is to separate as many cardiogenic cells as possible.  
To achieve this, the cells must be kept alive.  This is done by maintaining a sterile 
environment for the cells.  If the cells die because they are exposed to a non-sterile 
environment, then the cell separation was meaningless since the sample can no longer be 
utilized.  A non-sterile environment would contaminate the cells and make them of no 
use.  A sterile environment can either be in a cell culture hood, or in a fully enclosed 
sterile environment outside of the culture hood.   
 The device must keep cells alive throughout the entire separation and isolation 
process.  If the cells die at any point during the process, they are of no use.  The cells 
must be kept at a relatively constant pH, temperature, pressure, and be in a medium that 
supports them.  Excessive force must not be applied to the cells when trying to separate 
them, or at any point in the process.   
Pairwise Comparison Charts 
 
Pairwise Comparison charts, as shown in Tables 1-7, were used to help rank 
objectives early in the design process.  These charts compare the different design 
objectives in a paired fashion (Dym, 2004). 
  
29 
 
Table 1: Pairwise Comparison Chart of Main Objectives 
MAIN OBJECTIVES 
Isolates 
Cells 
Effectively 
Sort cardiogenic 
cells from non-
cardiogenic cells  
Keep separation 
between free cells 
and spheroid 
contained cells Reliable 
User 
Friendly Safe Total 
Isolates Cells 
Effectively x 1 1 1 1 1 6 
Sort cardiogenic cells 
from non-cardiogenic 
cells  0 x 1 1 1 1 5 
Keep separation 
between free cells and 
spheroid contained 
cells 0 0 x 0 1 1 3 
Reliable 0 0 1 x 1 1 4 
User Friendly 0 0 0 0 x 0 1 
Safe 0 0 0 0 1 x 2 
 
Isolates Cells Effectively =  6    6/21= .286 
Sort cardiogenic cells  
from non-cardiogenic cells =  5   5/21= .238 
 
Keep separation between free  
cells and spheroid contained cells= 3   3/21= .143 
 
Reliable=    4   4/21= .190 
User Friendly=   1   1/21= .048 
Safe=              +2   2/21= .095 
     21 
 
Table 1 compares the importance of isolating cells effectively, sorting cardiogenic 
cells from non-cardiogenic cells, keeping separation between free cells and spheroid 
contained cells, reliability, user friendliness, and safety compared with one another.  As 
shown, isolating cells effectively was found to be the most important objective. 
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Table 2: Pairwise Comparison Chart of Sub-Objectives of isolates cells effectively 
sub objectives of 
isolates cells 
effectively 
From 
spheroid From free cells Total 
From spheroid X 0.5 1.5 
From free cells 0.5 x 1.5 
 
From spheroid=  1.5   1.5/3= .500 
From free cells=            +1.5   1.5/3= .500 
   3 
 
Table 2 compares the importance of the sub-objectives of isolating cells 
effectively.  The sub-objectives are isolating cells effectively from the spheroid and from 
the free cells.  As shown, when ranked against one another, the two were found to be 
equally important.  
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Table 3: Pairwise Comparison Chart of Sub-Objectives of reliable 
sub objectives of 
reliable durable repeatable efficient Total 
durable x 0 0 1 
repeatable 1 x 1 3 
efficient 1 0 x 2 
 
Durable=  1   1/6=  .167 
Repeatable=  3   3/6= .500 
Efficient=  +2   2/6= .333 
   6 
 
Table 3 compares the importance of the sub-objectives of being reliable.  The sub-
objectives are durable, repeatable and efficient.  As shown, when ranked against one 
another, repeatable was found to be the most important.  
Table 4: Pairwise Comparison Chart of Sub-Objectives of efficient 
sub objectives of 
efficient 
isolates 
cells in 
hours 
high yield 
return Total 
isolates cells in 
hours x 0 1 
high yield return 1 x 2 
 
isolates cells in hours=   1   1/3= .333 
 
high yield return=   +2   2/3= .667 
    3 
 
Table 4 compares the importance of the sub-objectives of being efficient.  The 
sub-objectives are isolates cells in hours, and has a high yield return.  As shown, when 
ranked against one another, high yield return was found to be the most important. 
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Table 5: Pairwise Comparison Chart of Sub-Objectives of user friendly 
sub objectives of 
User Friendly 
easy to 
use automated easy to clean timely Total 
easy to use x 0.5 0 1 2.5 
automated 0.5 x 1 1 3.5 
easy to clean 1 0 x 1 3 
timely 0 0 0 x 1 
 
easy to use=  2.5   2.5/10= .250 
 
automated=  3.5   3.5/1-=.350 
 
easy to clean=  3   3/10= .300 
 
timely=   +1   1/10= .100 
   10 
 
 
 
Table 5 compares the importance of the sub-objectives of being user friendly.  
The sub-objectives are easy to use, automated, easy to clean, and timely.  As shown, 
when ranked against one another, automation was found to be the most important. 
 
Table 6: Pairwise Comparison Chart of Sub-Objectives of safe 
sub objective for 
safe 
safe for 
user safe for cells Total 
safe for user x 0 1 
safe for cells 1 x 2 
 
safe for user=  1   1/3= .333 
 
safe for cells=  +2   2/3= .667 
   3 
 
 
Table 6 compares the importance of the sub-objectives of being safe.  The sub-
objectives are safe for the user, and safe for the cells.  As shown, when ranked against 
one another, safe for the cells was found to be the most important. 
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Table 7: Pairwise Comparison Chart of Sub-Objectives of safe for cells 
sub objective for 
safe for cells sterile 
keeps cells 
alive Total 
sterile  x 1 2 
keeps cells alive 
 0 x 1 
 
Sterile=   2   2/3= .667 
 
keeps cells alive= +1   1/3= .333 
   3 
 
 
Table 7 compares the importance of the sub-objectives of being safe for the cells.  
The sub-objectives are sterile, and keeps cells alive.  As shown, when ranked against one 
another, being sterile was found to be the most important. 
 
Objectives Tree  
 
An objectives tree was used to help better understand the client statement.  It is a 
hierarchal list that branches out into a tree-like structure. Each main objective has a set of 
sub-objectives that helps clarify and give more detailed descriptions of the objectives 
above them in the tree. The main goal is located at the top of the tree and the objectives 
and sub-objectives then branched out below the main goal. The numbers assigned to each 
objective and sub-objective was given in accordance with the weighting they were given 
in the pairwise comparison charts in the previous section of this report. Figure 1 is the 
weighted objectives tree for this project. The objectives tree gives a more visual way to 
see the importance of each objective in the final design.  
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Figure 1: Weighted Objectives Tree 
Device
Isolates Cells 
Effectively 
0.334
From 
Spheroid 
0.500
From Free 
Cells 0.500
Sorts Cells 
0.278
Reliable 
0.222
Durable 
0.167
Repeatable 
0.500
Efficient 
0.333
Isolates Cells 
in hours 
0.333
High Yield 
return 0.667
User Friendly 
0.056
Easy to Use 
0.250
Automated 
0.350
Easy to Clean 
0.300
Timely 0.100
Safe  0.110
Safe for User 
0.333
Safe for Cells 
0.667
Sterile  0.667
Keep Cells 
Alive 0.333
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Design Constraints 
 
 The constraints of a design are the limitations or restrictions that are placed on the 
project.  The constraints for this MQP are time, cost, total isolation time of cells, sterility 
and resources availability.  The project must be completed by April 5, 2008 because this 
is one week before project presentation day and all aspects of the project must be 
finalized in order to create a complete and organized project presentation.  The total cost 
of the project should not exceed $468, as each student in the group was allotted $156 
each by the Worcester Polytechnic Institute’s Biomedical Engineering Department.  This 
will put limitations on the types of materials that are able to be used in the working 
prototype, but will force the group to be able to generate innovative ideas regarding 
alternate methods and materials used in the prototype.  The next constraint is the total 
amount of time it will take to isolate the cells.  The design must be able to isolate the cells 
in minutes or hours, rather than days or weeks.  By limiting the design with this 
constraint, it will allow the user to isolate cells in bulk in a time-efficient manner.  Next, 
the design must be able to isolate the cells in a sterile, non-toxic environment as not to 
damage, kill or compromise the viability of the cells in any manner.  This can be 
achieved by either having the design fit into a sterile lab hood, or by having the entire 
system enclosed in a sterile box.  Finally, the limitations on the resources the group will 
have access to while completing this project will constrict the design.  The limited 
amount of time to grow hMSCs to test the design with, as well as the solutions that they 
will grow in and the solutions that are used to isolate the cells will limit the amount of 
testing that the group is able to do to create a proven working prototype.  Also, access to 
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the major equipment in the lab, including incubators to culture the cells in, availability of 
a sterile lab hood if need be, and also the use of other equipment like a flow cytometer if 
needed.  These constraints will limit the project but it will also force innovative thinking, 
creative ideas and produce an original design prototype that will be able to achieve all the 
objectives within the scope of this project.  
Good Manufacturing Process 
 
 Good Manufacturing Practice (GMP) is a regulation for medical devices that is 
enforced by the U.S. Food and Drug Administration (FDA), more specifically the Center 
for Devices and Radiological Health (CDRH) (21 CFR Parts 808, 812, and 820 Medical 
Devices; Current Good Manufacturing Practice (CGMP); Final Rule., 1996).  The most 
up to date GMP practices are referred to as the current Good Manufacturing Practice 
(cGMP).  All manufactures of medical devices that are sold commercially in the United 
States must follow these practices.  The reasoning behind this is so that the American 
people receive medical devices that do what they are designed to do, and do not cause 
unwarranted injuries.  
 The GMP regulation set forth in the Quality System (QS) regulations are 
promulgated under section 520 of the Food, Drug and Cosmetic Act (CDRH, Medical 
Device Quality Systems Manual: A Small Entity Compliance Guide, 1999).  It requires 
that domestic or foreign manufacturers of medical devices intended for commercial 
distribution in the United States establish and follow a quality assurance (QA) program 
(CDRH, Medical Device Quality Systems Manual: A Small Entity Compliance Guide, 
1999).  The GMP rule is a flexible program.  It recognizes that companies and the 
medical devices that they manufacture can, and do vary greatly.  For this reason it is set 
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up as a list of rules on how to design and manufacture medical devices in the safest most 
effective way possible.  The rules listed in the cGMP apply only to those medical devices 
for which they are needed.   
 If a company is manufacturing only one device that is simple then a good portion 
of the rules are not going to apply because they are not needed do to the simplicity of the 
medical device.  This medical device can be manufactured safely without all the 
restrictions which may be needed for a more complicated device or factory which is 
manufacturing a variety of different devices at the same time.  The regulation requires 
that specifications and design controls be established for each medical device and that the 
finished devices meet these specifications.  This makes sure that each device does what it 
is supposed to.  By doing this, the GMP regulation helps assure that medical devices are 
safe and effective (CDRH, Human Factors Implications of the New GMP Rule Overall 
Requirements of the New Quality System Regulation, 1998).  
 Design controls are an interrelated set of practices and procedures 
that are incorporated into the design and development process, i.e., a 
system of checks and balances. Design controls make systematic 
assessment of the design an integral part of development. As a result, 
deficiencies in design input requirements, and discrepancies between the 
proposed designs and requirements, are made evident and corrected earlier 
in the development process. Design controls increase the likelihood that 
the design transferred to production will translate into a device that is 
appropriate for its intended use (CDRH, Design Control Guidance For 
Medical Device Manufacturers, 1997).  
Here the FDA gives its definition and explanation for the need of design controls.    
 The GMPs for medical devices were updated when analysis of recalls and adverse 
reaction reports showed that about half of reported device failures involve traditional 
GMP problems. Between 1985 and 1989, FDA compiled data through its recall database 
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that demonstrated that 45 to 50 percent of all device recalls stemmed from poor product 
design (including problems with software) (CDRH, Human Factors Implications of the 
New GMP Rule Overall Requirements of the New Quality System Regulation, 1998).  
For this reason, Congress passed the Safe Medical Devices Act (SMDA) of 1990, which 
gives FDA authority to require good manufacturing practices necessary to ensure proper 
device design (CDRH, Human Factors Implications of the New GMP Rule Overall 
Requirements of the New Quality System Regulation, 1998).  This act was the impetus 
for ―Medical Devices; Current Good Manufacturing Practice (cGMP), final rule‖, which 
required design controls to be implemented into the design and manufacturing of medical 
devices.   
 These revised GMPs for medical devices were incorporated into a quality system 
regulation.  
The Quality System Regulation includes requirements related to the 
methods used in, and the facilities and controls used for, designing, 
manufacturing, packaging, labeling, storing, installing and servicing of 
medical devices intended for human use. The revised GMP Regulation 
was released as a final rule on October 7, 1996. The section that deals 
specifically with design controls is section 820.30 of Title 21, of the Code 
of Federal Regulations ("21 CFR"). 21 CFR 820.30 requires 
manufacturers to establish and maintain procedures to control and verify 
device design to ensure that design requirements are met. More 
specifically, it requires manufacturers to establish and maintain plans that 
describe or reference the design and development activities and indicate 
responsibility for their implementation. It further requires manufacturers 
to establish and maintain procedures to ensure that design requirements 
relating to a particular device are appropriate and address the intended use 
of the device, including the needs of users and patients. It also requires 
manufacturers to establish and maintain procedures to ensure that design 
output meets the design input requirements. The regulation is effective 
June 1, 1997 (CDRH, Human Factors Implications of the New GMP Rule 
Overall Requirements of the New Quality System Regulation, 1998).  
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cGMP and Our Device 
  
 The device designed in this project falls under the category 862.2750 Pipetting 
and diluting system for clinical use. 
 
Subpart C--Clinical Laboratory Instruments 
Sec. 862.2750 Pipetting and diluting system for clinical use. 
 
(a) Identification. A pipetting and diluting system for clinical use is a 
device intended to provide an accurately measured volume of liquid at a 
specified temperature for use in certain test procedures. This generic type 
of device system includes serial, manual, automated, and semi-automated 
dilutors, pipettors, dispensers, and pipetting stations. 
 
(b) Classification. Class I (general controls). The device is exempt from 
the premarket notification procedures in subpart E of part 807 of this 
chapter subject to 862.9. 
 
[52 FR 16122, May 1, 1987, as amended at 65 FR 2309, Jan. 14, 2000]  
(CDRH, [Code of Federal Regulations] [Title 21, Volume 8], 2007) 
 
 This device must follow cGMP practices.  Only the class I devices with an 
asterisk (*) are also exempted from the GMP regulation, except for general requirements 
concerning records (820.180) and complaint files (820.198), as long as the device is not 
labeled or otherwise represented as sterile (CDRH, Medical Device Exemptions 510(k) 
and GMP Requirements, 2008).  862.2750 Pipetting and diluting system for clinical use 
are not exempt from cGMP regulation.  This means that if this medical device was 
manufactured and sold commercially in the United States it would have to follow cGMP 
regulations.       
Functions 
 
The functions of the device must include several characteristics.  The device will 
have several wells in order to speed the process.  The device must also isolate cardiogenic 
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cells into single cardiogenic cells. Then, the cardiogenic cells must be sorted from the 
non-cardiogenic cells.  Through this process, the device must maintain cell viability and 
ultimately produce single cells.  The cells must be isolated from the spheroid body and 
from the plate.  It must provide the operator with a user interface or manual of 
instructions.  The cells must be kept sterile throughout the entire process.  The 
temperature of the media and the O2 and CO2 must be kept constant as well.  The 
operator must use gentle handling throughout this process.  
Specifications 
 
The device must work with the cell culture media.  It must keep the cells at a 
constant temperature of 37°C ± 1°C.  It must maintain a 5% CO2 concentration.  The 
device must isolate at least 50% of the single cells from spheroid bodies.  The device 
must produce 80% or greater pure population of sorted cardiogenic cells.  The device 
must produce a cell viability of at least 80% for the sorted cardiogenic cells.  Starting 
with approximately 12,500 hMSCs in the spheroid body will theoretically yield at least 
2000 live, cardiogenic single cells if these percentages are followed.  Increasing the yield 
at one of these stages will increase the final yield.   
Design Alternatives 
 
Design Alternative 1  
 
The spheroids are grown until the spheroid body is ready to be harvested, at this 
stage Design Alternative 1 begins.  The cells are trypsinized to remove them from the cell 
culture container.  The spheroid body is aspirated with a pipette and set aside for 
trituration.  The free cells are then washed in media to neutralize the trypsin.  The free 
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cells are pipetted to make sure that they are isolated into single cells.  These single free 
cells are then placed in a centrifuge vial.  A similar process is followed for the 
preparation of the spheroid body cells.  These cells are pipetted until they are isolated into 
single cells.  They are then place in a centrifuge vial.  After centrifuging the cells at low 
speeds the vials are removed.  The cells at the bottom of the vials are removed by either 
pipetting them up or by decanting the top solution.  Once the cells at the bottom of the 
vial are isolated they are resuspended into media.  These cells can then be tested for 
cardiogenic markers and tested to see if they are viable.  This process is completed 
manually.      
To improve upon this process the trituration of the spheroid cells can be carried 
out in an automated process.  The vials containing the cells can be placed in a rotating 
shelf.  A series of various sized pipettes can then drop down and pipette the cells for a set 
amount of time, then rise up.  The plate containing the vials can then rotate to the next 
position where a smaller sized pipette would drop down and pipette the cells.  This 
process would continue for some time until the cells were pipette through the smallest 
pipette and were isolated into single cells.  A diagram illustrating this design is shown in 
Figure 2. 
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Figure 2: Design Alternative 1 
Design Alternative 2 
 
 Once the spheroid bodies have been plated, and sit for several days, the media 
containing cells that surrounds the spheroid body will be carefully sucked up by a pipette 
and placed into separate wells underneath and automated trituration system and on top of 
a vibrating plate.  Six pipettes move up and down in the system above the wells on the 
plate and triturate the cells in each well by pumping the fluid in and out of the well. The 
vibrations from the plate underneath help to isolate the cells further. After several 
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minutes, everything will be pipetted of each of the wells manually and placed into 
separate vials. The vials will be centrifuged at a certain speed for a given amount of time. 
The heavier (cardiogenic) cells should sink to the bottom of the vial when centrifugation 
is complete. These cells will then be marked and examined under a microscope for 
cardiogenic markers and cell viability.  A diagram illustrating this design is shown in 
Figure 3. 
 
Figure 3: Design Alternative 2 
Design Alternative 3 
 
 In this design alternative the process of isolating the spheroid cells is automated. 
But, before entering the device, the free cells are trypsinized and pipette from the 
spheroid plate, leaving the spheroid behind. Next, these free cells are put in a vial with 
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cell media to be later sorted. Next the plate of now just spheroids is placed on the 
conveyer belt at the entrance of the device. The plate then slides through the entrance 
where it enters a completely sterile environment. At the top of the box there is a 
removable pipette shelf that is replaced with new sterile pipettes every use. The pipettes 
are then lowered into the box directly on top of the spheroids. The spheroids are then 
triturated for a predetermined amount of time, until desired isolation is met.  Trypsin is 
then added to the isolated cells to release them from the plate. The pipette shelf is then 
removed with the pipettes containing the now isolated cells. These cells are then placed 
in a separate vial that contains cell media to deactivate the trypsin. These two vials are 
then placed in a centrifuge in order to sort them into cardiogenic and non-cardiogenic 
cells. Finally, the cardiogenic cells, which are heavier, are sucked from the bottom of 
each vial a tested for cell viability and cardiogenic markers. The live, healthy, 
cardiogenic cells are then used.   A diagram illustrating this design is shown in Figure 4. 
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Figure 4: Design Alternative 3 
 
Design Alternative 4 
 
 The hMSCs will be plated and after several days, placed into an automated 
trituration system. Once triturated, the cells will be placed into a separate holding 
container. Some sheet of material soaked in a substance that attracts cardiac cells will be 
dipped into the media holding the hMSCs. The cells will stick to the sheet. The sheet will 
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then be placed in a media containing trypsin to release the cells from the sheet. These 
cells will then be marked and examined under a microscope for cardiogenic markers and 
cell viability.  A diagram illustrating this design is shown on the top portion of Figure 5. 
Design Alternative 5 
 
The hMSCs will be plated and after several days, placed into an automated 
trituration system. Once triturated, the cells will be placed into a separate holding 
container. A device sending out electrical impulses will repel the cardiogenic cells toward 
the opposite end of the holding container, the cells will fall onto a sloped edge and drop 
down into a vial of media. These cells will then be marked and examined under a 
microscope for cardiogenic markers and cell viability.  A diagram illustrating this design 
is shown on the bottom of Figure 5. 
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Figure 5: Design Alternatives 4 and 5 
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Design Matrix 
 
    
    
 
Figure 6: Design Matrix 
 
 
Design Matrix Constraints 
 
Time 
 
 The constraint of time was met by all five designs.  The design should meet its 
purpose in less time than it would take the user to complete the process manually.  
Budget 
 
Money is one of the constraints for this project.  This project has a limited budget 
and all of the designs had to fall within this amount to be considered.  All the design 
alternatives except design alternatives 4 and 5 were determined to have a projected cost 
that falls within the budget.       
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Sterility and Resources 
 
 The constraint of sterility was also met by all of the designs.  All of the designs 
can either be fit inside a sterile hood, or are themselves contained in a sterile box.  The 
resources for the designs were only met by designs 1, 2 and 3. These 3 designs follow the 
same basic procedure and the materials and resources will all be available.  Design 4 did 
not meet the criteria for resources because the substance used for attracting the cardiac 
cells may not be available to the team.  Design 5 also did not meet the resources criteria 
because a magnetic separator is not available for the team at this time.  If it does become 
available, then the resource criteria will be met. 
 
Design Matrix Objectives 
 
Isolates Cells Effectively 
 
The five designs received different rankings in their ability to isolate cells 
effectively.  The first three designs received an equal score of 33/33 since each design 
would work through trituration, which is a proven effective method of isolation of other 
types of cells.  The other two designs would require use of methods that are uncommon.  
There are many factors that would make designs four and five inefficient.  Design four 
could be inefficient since the material may also absorb some of the non-cardiogenic cells, 
not all of the cells, or drop some of the cells when pulls from the media.  Design five 
could be inefficient since the magnetic waves could push non-cardiogenic cells off the 
plate if those cells are stuck to the cardiogenic cells.  It might also not be powerful 
enough to repel the cardiogenic cells. Therefore, designs four and five received a lower 
score of 16.5/33. 
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Reliable 
 
The different design alternatives were considered to be reliable if they were 
automated, had few parts, and would require little user interaction to complete the 
isolation and separation process.  The design alternative was considered unreliable if the 
device required a large amount of user interaction, had many moving parts, and require 
constant maintenance.  Based on this criteria design 1 received a score of 15/22.  This 
design alternative required a large amount of human interaction and was not automated.  
Design alternatives 2 and 3 received scores of 22/22 because they are both automated and 
require little user interaction.  Design alternatives 4 and 5 received 8/22 these methods 
require user interaction and may not always separate the cells as wanted.         
 
User friendly 
  
User-friendly is defined as a device or method that requires little user interaction 
and which is automated.  Design alternative received a 0/6 for this because it is all done 
by hand and not automated.  Design alternatives 2, 3, and 5 received a 6/6 because they 
are automated and easy for the user to operate.  Design alternative 4 received a 3/6 for 
this objective because it is mostly automated, but requires some user interaction. 
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Safe 
 
In the design matrix the final objective to reach for each design was ―safe.‖  This 
means that the design would be safe for the user to operate and safe for the cell, meaning 
that the design would be able to maintain cell viability and cardiogenic traits.  All 5 
designs completely met this objective; therefore they all received an 11/11.  The 
reasoning behind this decision is that the designs show no potential hazards for the user 
or the cells.  
 
 
Final Design 
 
The final design that we chose is a combination of design alternatives two and 
three.  The objective of this design is to automatically separate spheroid bodies or other 
clumps of cells into single cells.  This fully automated design is described as follows.   
 The overall shape of the design is a rectangular box frame.  The base frame has 
two sub frames.  The first sub frame is on the bottom of the main frame and holds both 
the 24 well plate with the spheroid bodies and a test tube rack.  This bottom sub frame 
moves horizontally.  The horizontal motion of the sub frame is guided by two guide 
tracks, one on each side of the sub frame, parallel to the direction of motion.  The bottom 
sub frame is moved by a pulley system attached to a motor which is controlled through 
LinControl Software© provide by Lin Engineering (Santa Clara, CA).    
The second sub frame is located near the top of the base frame and holds the 
pipette cart, motor and thread screw that controls the movement in the x direction.  This 
sub frame will be referred to as the pipette frame.  This sub frame moves up and down on 
four guide tracks.  The pipette sub frame is powered by a motor attached to a thread 
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screw system which is controlled through LinControl Software© provide by Lin 
Engineering (Santa Clara, CA).  This device allows the user to load the necessary 
components into the machine and press the start button.  After this, the device takes care 
of everything else.  The device can take solution from the test tubes and but it into the 24 
well plate containing the spheroid bodies and cells.  It can also pipette the cell solution to 
separate the cells into single cells.  This allows the device to automatically triturate the 
cells and separate them into single cells.     
 
Figure 7: CAD Drawing of Preliminary Design Frame 
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Figure 8: CAD drawing of final design 
 
Figure 8 above is a CAD drawing of the final design that incorporates the thread 
screw, stepper motors and pulley system used to automate the device.  The base plate and 
all its inserts can be seen as well.   
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Figure 9: Right isometric photograph of the device 
 
Figure 9 above shows a right isometric view of the finished device and all its 
components.  The pulley system is located on the top which is run by a stepper motor.  
This lifts and lowers the track.  The cart is attached to the thread screw run by a motor.  
This moves the cart left and right for the transfer of materials. 
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Figure 10: Left Isometric view of device 
 
Figure 10 above shows a left isometric view of the finished device and all its 
components.  The motor on the left powers the thread screw, as shown.  The bottom unit 
can be seen in this photograph, which houses the 24 well plate, the removable insert 
containing eppendorf tubes, the pipette tip remover and the pipette holder. 
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Figure 11: Front view of device 
 
Figure 11 above is a front view of the device and all its components.   
 
 
Figure 12: Photograph of Pulley System and thread screw 
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Figure 12 above shows how the pulley system is connected.  40 lb test fishing line 
was used within the pulley system since it is strong enough to withstand the weight of the 
track.  The line is fed through the hole on the aluminum that houses the mounted bearing.  
The line is then crimped to be held in place.  The crimp was used rather than a knot since 
it would hold more effectively. 
 
 
Figure 13: Photograph of Pipette cart 
 
Figure 13 above is a photograph of the moving pipette cart.  This pipette cart 
contains 4 pipettes that connect to a syringe pump that activates the triturating 
mechanism of the device.  The pipette cart moves both left and right to transport 
materials from one location in the device to another. 
 
58 
 
 
Figure 14: Photograph of removable inserts 
 
 Figure 14 above is a photograph of the removable inserts within the base of the 
device.  On the left is the 24 well plate, followed by the eppendorf tube holders, the 
pipette tip remover and then the pipettes (not pictured). 
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Figure 15: Pipette removal 
 
 Figure 15 above shows the pipette tip remover which gently removes the used 
pipettes tips from the pipette cart once the tips are used.  The rectangular hole will house 
a small trash bag that will collect the biohazardous tips when the process is complete.  
The sterile pipette tips can be seen following the pipette tip remover. 
60 
 
 
Figure 16: Photograph of top stepper motor 
 
 
Figure 16 above shows the top stepper motor connected to the upper part of the 
device. There is a small pulley connected to the motor containing several feet of 40 lb test 
fishing line.
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Motors 
 
 One of the basic parts of our design is its ability to automatically isolate cells into 
single cells.  To do this effectively the device must be able to move both vertically and 
horizontally in a controlled fashion.  To automatically move the sub frames you need a 
source of movement.  For this we chose stepper motors.  Stepper motors were chose to 
move the sub frames within the device both vertically and horizontally because they can 
be easily controlled and are reasonably priced.  Once the type of motor to use was chosen, 
it was required to determine the specification for the movement that the device would 
undergo.  This allowed the acquisition of the proper motors.  To determine the 
specifications of the motors, the weight that each individual motor would have to move 
was calculated in the Table 8: Weight of Vertical Assembly and Table 9: Weight of 
Horizontal Assembly below.     
     
Table 8: Weight of Vertical Assembly 
Part 
number Description 
Quantity 
(units or ft) 
Weight 
(lbs.) 
sub 
total 
1010X97" Aluminum T-Slotted Framing System 1010 7.7 0.51 3.92 
6715 10 S Single Flange Linear Bearing 4 0.21 0.82 
2281 10 S Roller Wheel 4 0.07 0.28 
3090 
10 S 10-32 Double Anchor T-Nut T Short 
Assembly 12 0.06 0.74 
  motor weight (estimated) 1 5.00 5.00 
  plastic top pipette holder (estimated) 1 2.00 2.00 
  screw assembly weight (estimated) 1 3.00 3.00 
  Grand total     15.77 
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Table 9: Weight of Horizontal Assembly 
Part 
number Description 
Quantity 
(units or ft) 
Weight 
(lbs.) 
sub 
total 
1010X97" Aluminum T-Slotted Framing System 1010 1.72 0.51 0.88 
6715 10 S Single Flange Linear Bearing 4 0.21 0.82 
2281 10 S Roller Wheel 4 0.07 0.28 
  motor weight? 1 5.00 5.00 
  plastic top pipette holder 1 2.00 2.00 
  screw assembly weight ? 1 3.00 3.00 
  Grand total     11.98 
  
Once the weight that the motors would have to move was determined the torque 
can be calculated based upon the motion transfer mechanism.  The general specifications 
of the different motors can be found in Table 10: Motor and Lead Screw Specifications 
below.  The axial load is calculated by assuming that there is about a 0.1 coefficient of 
friction between the horizontal sub frame’s wheels and the bar they run along.  This 
would give an axial load of 1.2 lbs.   
Table 10: Motor and Lead Screw Specifications 
motor speed (in/sec) 
load (weight in 
lbs.) 
duty cycle 
(min) 
horizontal 3 ~1 (axial) ~1 
vertical 1 16 ~1 
 
The motors also have a torque requirement that will be explained in the next 
section entitled, ―Motion Transfer and Torque.‖ 
Motion Transfer and Torque 
 
 After consideration of a variety of motion transfer systems it was decided that the 
device would use lead screws with nuts to position the sub frames containing the pipettes 
in the proper position.  Lead screws were chosen because they allow for precise control 
of the nut relative to the motor revolutions.  A ball screw mechanism would be more 
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precise, but due to cost associated with it the extra precision was not worth the additional 
cost.  An Acme lead screw assembly was chosen because these lead screws have large 
amounts of engineering information on them and they are relatively inexpensive and 
readily available.   
The use of a stainless steel (SS) lead screw with a plastic nut was decided upon 
for a number of reasons.  This combination requires no lubricant.  Lubricant could 
contaminate the cells being worked with.  Using no lubricant also allows for easy 
cleaning and sterilization.  The parts can be easily wiped down with soap and water to 
clean them, and then sterilized with 70% ethanol.       
 A technical representative from Nook Industries (Cleveland, Ohio) was consulted 
with to find the proper size lead screw for the specifications required.  It was determined 
that the Acme lead screw that would work the best would be a ½‖ lead screw with two 
threads per inch.  The threads per inch could be increased to increase accuracy, but this 
would lead to a higher PV value, or the unit pressure on the nut (P) and surface velocity 
at the nut/screw interface (V).  The ½‖ SS lead screw with two threads per inch and a 
plastic nut would meet the specifications of both the horizontal and vertical motion.  This 
would also allow for easy replacement if one nut broke you would not have to have 
different size nuts on reserve.     
 Once the motion transfer system was chosen, the torque that each motor needs to 
produce can be calculated.   This can be calculated by using the torque formula in Figure 
17: Torque Equation below.  
 
Figure 17: Torque Equation 
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 The alternative is to just look up the lead screw nut assemble number for torque 
to raise one pound.    For this particular lead screw nut assemble, 0.107 (in-lb) of torque 
is required to raise one pound.  So, for the vertical motor multiple 0.107 times 16 lbs.  
This gives 1.7 in-lbs. of torque needed to raise the vertical sub frame.  This number is 
then doubled to 3.4 in-lbs. to account for friction and give some wiggle room.  The same 
approach is used for the horizontal lead screw assemble.  0.107 times 1 lb. is 0.107 in-lb 
of torque, times two yields .214 in-lb of torque.            
 
Controlling the Device  
 
Stepper motors were chosen as the means to moving the device in the x and y 
directions.  The motors that were chosen for this device are from Lin Engineering out of 
Santa Clara, California.  The SilverPak series was chosen for both motors because it is a 
package of motor, controller and driver and they are easily programmable.  For the x 
direction the SilverPak 17C series was chosen.  The stepper motor is a NEMA 17 1.8º 
Bipolar step motor, part # 4118M.  It has a maximum holding torque of 45 oz-in.  For the 
y direction, the SilverPak 23C series was chosen because it has more holding torque at 
294 oz-in.  The higher holding torque was needed for the y direction because it has to be 
able to withstand the weight of the x direction motor assembly, lead screw and pipette 
apparatus.  This stepper motor is the NEMA 23 1.8º Biopolar step motor, part # 5718L. 
The calculations for finding the holding torque were described in the above sections.  
The program that is going to be used to control the motors is supplied by Lin 
Engineering and has simple commands that allow it to travel certain distances.  The 
coding is done through alphanumeric commands that account for the number of rotations 
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the stepper motor is doing.  An example of the program is shown in Figure 18.  Figure 19 
shows the flow chart created by the team which outlines the steps the program must 
follow. 
 
 
Figure 18: Screen Shot of Stepper Motor Program 
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Figure 19: Program Flow Chart 
 
The entire program is completely outlined for the 17C motor and is shown in 
Appendix 4.  The program for the 23C motor was not completed because testing of the 
device had not been done.  In order to completely write the program, timing of the 
syringe pump and the amount of time it took for the shelf of the device to be raised and 
lowered would have to be taken into consideration.  This testing could not take place 
because both of the stepper motors malfunctioned.  The 17C stopped turning in the 
counter clockwise direction and the 23C would continuously seize up and would have to 
be manually pushed to start running again.  Lin Engineering had been contacted with 
these problems and Technical Support was unable to resolve them.  If these problems can 
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be resolved, then programming of the 23C motor can be completed with specific timings 
to allow for the isolation process to be completed.  
Syringe Pump  
 
 In order to transfer materials inside the device during the isolation process a 
means of transportation was needed.  It was decided that a syringe pump would be able to 
aspirate and discharge material as well triturate the cardiogenic cells in order to isolate 
them from the spheroid body.  The MQP group consisting of Michael Fakjarzadeh, 
Gregory Fredette and Emily Martin had used a syringe pump to complete their project 
entitled ―A Scaffold for Cardiac Regeneration.‖  Because both this project and their 
project were advised by Professor Gaudette, they were able to share this program for this 
project.  This program was developed in LabView 8.1 and the Front Panel of this 
program is shown in Figure 10.  It has not been altered to fit the needs of this device, but 
this problem will be addressed in the Future Recommendations section of this paper.  
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Figure 20: Front Panel of LabView 8.1 Program 
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Experimental Methods 
Non-automated Testing 
 
In order to test the efficiency of the device, the team completed manual 
experimental tests in the laboratory.  Spheroid bodies were grown using the hanging 
droplet method and plated in a 24 well plate after 3 days.   
The initial testing for proof of concept of the device started with the culture of 
Human Mesenchymal stem cells. The passage 9 cells were thawed in a 37˚C water bath 
for one minute.  These cells were aspirated out of the initial tube and added drip-wise to a 
culture flask.  8mL of DMEM supplemented with 10% Fetal Bovine Serum (FBS) and 
1% P/S was added to the flask and the flask incubated for 4 days. 
 After 4 days, the cells in the flask were trypsinized with 6 mL of trypsin for 7 
minutes, aspirated and added to a 15 mL vial holding 4 mL of 10% FBS media.  The cells 
were spun down in the centrifuge at 3000rpm for 5 minutes.  The media was poured off 
and 1 mL of DMEM supplemented with 20% FBS and 1% P/S was added drip-wise to 
the cell pellet.  A cell count was conducted and showed that there were approximately 
1,810,000 cells in the vial.  
 
1
st
 count = 89 cells 
2
nd
 count = 92 cells 
89 + 92 = 181 cells 
(181 cells/10 squares) x 10
4 
x 10 x 1mL = 1,818,000 cells/mL 
15,000 cells/20 µL = 1,810,000 cells/x 
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x= 2413.33 µL or 2.413 mL 
Add 1.413 mL of 20% FBS media to the cell suspension 
1,810,000/2413 µL = 500,000/y 
Y = 666.6 µL 
2413-666.6 = 1746.4 -666.6 = 1079.8 
Add 666.6 µL cell suspension to two new cell culture flasks and add 8mL 10% FBS 
media 
 
1079 µL/20 µL = 53 spheroids 
 
20µL droplets of media were placed onto every other circle on the lid of a 96 well 
plate.  The plate was carefully flipped over and laid on top of the bottom section so the 
droplets were hanging upside down.  Every day for 3 days, the lid was flipped over and 
another 20µL droplet of 20% FBS media was added to each droplet.  
 On the third day, round spheroids had formed and the lid was flipped over one 
final time.  The media was aspirated off of each spheroid and rinsed with a 20 µL droplet 
of PBS.  The spheroids were drawn up and released into the center of individual wells of 
a 24 well plate (every other well).  The empty wells contained sterile PBS to provide 
moisture within the container and prevent drying.  After 8 hours, drying out within the 
wells was observed, so 200 µL of 20% FBS media was added to each well to prevent cell 
death as a result of drying.  Every day for 2 more days, 50 µL of 20% FBS media was 
added to each well that contained a spheroid.  On the third day after the cells had been 
plated, testing was conducted. 
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Using P1000 pipette, 100 µL 20% FBS 1% P/S media was added to 5 eppendorf 
tubes. Using the P1000 pipette, varying amounts of trypsin were added to the wells that 
contained spheroids with cells coming off.  Since there were a limited number of 
spheroids with cells coming off, the tests were conducted carefully under the microscope 
while continuous observation took place.  
Automated Testing 
 
 Automated testing would utilize the same testing procedure of the non-automated 
testing but will utilize the syringe pump that is available in Gaudette’s Laboratory. This 
will insure that the results of the non-automated testing would be reproducible by the 
syringe pump. Once this testing is complete, testing of the device would occur. This 
would include running the LabVIEW® program that was controlling the syringe pump in 
line with the stepper motor programs and making sure that the precision of the pipette 
tips is accurate and that all of the systems are working together, the syringe pump, the 
motors and the software. This testing was not completed due to technical difficulties with 
the stepper motors and time constraints of this project. This setback was described in the 
Motion Control section and will be addressed in the Future Recommendations section of 
this paper.  
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Results 
 
Testing was conducted in the wells containing plated spheroids.  Using the P1000 
pipette, 200µL of trypsin was added to a well containing a spheroid (all wells also contained 
200µL of media) and the well was observed for several minutes under the microscope. 
After 20 minutes, neither the free cells nor the spheroid still had released from the bottom 
of the plate.  300µL of trypsin was added to another well containing a spheroid and the well 
was observed for several minutes under the microscope. After 10 minutes, neither the 
free cells nor the spheroid had released from the bottom of the plate. 500 µL of trypsin was 
added to another well containing a spheroid and the well was observed for several minutes 
under the microscope. After 5 minutes, the free cells had released from the bottom of the 
plate.  Two more tests were completed repeating the addition of 500 µL of trypsin to a well 
containing a spheroid, and the result was the same in both cases.  It took only 5 minutes for the 
free cells to release from the bottom of the well.  Using a P1000 pipette, the free cells and 
media were aspirated from the well and transferred into the eppendorf tube containing 
100 µL 20% FBS 1% P/S media.  Using the P1000 pipette, varying amounts of trypsin 
were added to the spheroid starting with 100 µL every 30 seconds.  After 2 minutes the 
spheroid released from the bottom of the plate.  Manual trituration took place for one 
minute and the cells appeared to have isolated into single cells under a 4X magnification 
in the microscope. During each step of the experiment, the cells were observed for cell 
isolation.  Table 11 shows the results of this testing.  Figure 21 below is a photograph of a 
spheroid with cardiogenic cells coming off that was taken during this testing. 
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Table 11: Results of Cell Testing 
Well # Media Trypsin Observations 
1 200µL 200µL No changes, even after 20 minutes 
2 200µL 300µL No changes 
3 200µL 400µL Few cells released from the bottom of the plate around 
the spheroid after 10 minutes 
4 200µL 500µL Cells released from the bottom of the plate around the 
spheroid after 5 minutes.  The cells were aspirated off 
and 100 droplets of trypsin were added every 30 seconds 
until the spheroid released from the plate bottom at 2 
minutes.   The spheroid was triturated for 1 minute once 
per second and the spheroid appeared to have isolated 
into single cells under the 4X magnification. 
5 200µL 500µL Test was run a second time with same results 
6 200µL 500µL Test was run a third time with same results 
 
 
Figure 21: Photograph of Spheroid at 4X 
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Analysis and Discussion 
 
 Through the cell testing outlined in the section above, it was found that if 500 µL 
of trypsin is added to a well of a 24 well plate containing a spheroid and 200µL of media, 
then the free cells can be isolated without disturbing the spheroid body.  It was also found 
that if 500 µL of trypsin is added to the spheroid body once the free cells are aspirated, it 
will take approximately 2 minute for the spheroid to release from the bottom of the well.  
Futhermore, if the spheroid is triturated for one minute after releasing from the bottom of 
the well, the spheroid body can be isolated into single cells.  This device will be able to 
utilize the results of this manual testing in order maximize cell isolation.  
 This device completely automates the process of isolating cardiogenic cells.  This 
will allow any laboratory utilizing this device to maximize productivity of trained 
personnel.  This will reduce the amount of time that the technicians spend isolating the 
cells and will also eliminate human error during the process.  Human error is reduced 
because the system is fully automated and the device is both accurate and precise so the 
inputted values are delivered every time.  This will in turn increase the amount of viable, 
cardiogenic cells that will be produced.  
 This device can easily be installed by one person into the bio-safety cabinet as it 
weighs less than 40 lbs and only needs a 24V DC power supply to power the device.  The 
device can easily be moved as it is only 3 square feet and this enables it to be moved 
from location to location and shared between different laboratory spaces.  Once the 
motors have been programmed to the customer’s needs, there is no need for additional 
PC support.  The process is saved in the motors’ memory and will begin the isolation 
process each time the device is powered up.   Another benefit of the compact size of the 
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device is that it is able to fit into a bio-safety cabinet which will ensure the sterility of the 
device, materials and cells.  This will allow for maximum cell viability.  
 This device is extremely versatile.  The base plate has machined holes that are 
able to house different inserts for a variety of uses.  For example, this device is 
customized to effectively isolate cardiogenic cells from a standard 24 well plate that the 
spheroid bodies are grown in.  New inserts can be machined to accommodate different 
size plates, pipette tips and eppendorf tubes.  This allows for this device to automate a 
number of different isolation processes and could also be used to make dilutions of 
various solutions used in the laboratory.  Speeds, pipetting times, and amounts of fluid 
being transferred can be altered because the motors and syringe pump programming can 
be adjusted to satisfy the user requirements.  
 This device organizes the large quantity of materials that are used in the isolation 
process.  All of the supplies needed are strategically located within the base plate of the 
device in order to maximize the efficiency of the process and decrease contamination.  
Because everything is securely contained in the base plate there is less chance of 
accidental spilling which cuts waste and prevents contamination.  
 Furthermore, this device is cost-effective.   It is able to be manufactured for 
approximately $1200 and is constructed out of materials that are commonly found in 
industry.  This is significantly less than other automated devices on the market that range 
from $15,000 to $25,000.  For example the Precision ™ Microplate Pipetting System 
from BioTek® (Winooski, Vermont) was quoted to be $15,300, not including software 
and supplies.  This is only designed for 8-channel liquid transfer capability, and therefore 
does not have the versatility of the device designed through this project.  This quote can 
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be seen in Appendix 5. In addition to the cost effectiveness of this device it is also easily 
assembled and can be programmed to fit any laboratory’s needs.   The many benefits of 
this device make it an invaluable addition to any cell research laboratory.  
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Conclusions 
  
The objective of this Major Qualifying Project was to develop a method for 
isolation of cardiogenic cells produced through spheroid body formation.   Through the 
team’s cell testing, a method for isolation of cardiogenic was discovered and a device 
was constructed that has the potential to fully automate this method.  As described in the 
client statement, this device will allow for maximized cell isolation within a completely 
sterile environment.  Future testing of this device will produce results on whether or not 
the device has the ability to retain cardiogenic potential. 
This device has been designed for manufacturing.  It is easy to assemble, made 
out of materials commonly used in industry, and is able to fit into a bio-safety cabinet to 
maintain sterility.  The device is fully automated to save the user time and reduce human 
error.  It is the start of producing cardiogenic cells from the laboratory bench to the 
patient bedside.  These cardiogenic cells could be delivered to patients to potentially treat 
cardiovascular disease in the future.  
 
Future Recommendations 
   
For the purposes of the device working as effectively as indicated, we recommend 
that two types of tests be conducted on this device.  It should undergo mechanical testing 
to ensure that the motors are in sync with the syringe pump, and to test the accuracy and 
precision of the device’s movements in both the x and y directions.  
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We also recommend that additional cell testing be completed in order to verify 
that this device maintains cell viability.  Due to time constraints, cell viability testing was 
unable to be completed.  This can be completed through a live/dead cell stain.  
The syringe pump program needs to be written in such a way that it will pick up 
the directed amounts of media and trypsin, triturate at the correct speeds, and do this in 
the correct timing sequence.  
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APPENDIX 1: Step by Step assembly 
 First please open and lay out all parts.  Please check to make sure you have all the 
parts you are supposed to.  Compare parts to the bill of materials. 
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Tools Required 
 Phillips head screw driver 
 Allen wrench 
 Pliers 
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Assembly of individual sub assemblies 
Sub assembly one, roller cart 
 
  
Fasten the 4‖ and 6.253‖ pieces together as shown in the picture using the double 
anchor fasteners.  Make sure that you slide in two 80/20 nuts onto the underside of each 
of the 6.253‖ pieces.  Once the rectangle is formed you can attach the support beams to 
the underside of the square using ¼-20 screws that are ½ inch.  Also make sure to slide 
two 80/20 nuts onto the opposite side of the aluminum and four 80/20 nuts onto the other 
side where the nut bracket will be attached.  Now you can drop it the pipette holder.  The 
pipette tips can then be placed into the pipette tip holder.  The nut bracket can now be 
attached to the cart frame with ¼-20 screws that are ½ inch long.  The pipette cap can 
then be secured over the pipette tip tops.  This is secured using two more of the 4 inch 
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support beams attached with ¼-20 screws into the 80/20 nuts.  Next attach the wheels 
onto the four inch pieces.  Wheels should be attached one inch from the ends.  Place the 
pipette holder top piece in place.  
 
Sub assembly two, outside frame 
 
 
To assemble the outside frame but together the parts shown in the asembly.  Make 
sure to tighten all the screws securely.  The top peieces should be relatively level.  Make 
sure when assembling the top rectangle portion to slide the 5.5 inch cross section bars 
into place.  Make sure that each of the middle 5.5 inch cross section bars each have two 
80/20 nuts slide into them.  Next attache the 23 mounting plate to these cross bars with ½ 
inch long 1/4-20 screws.  These screws should be low profile so the fit into the 
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countersunk holes.  Once this is complete you can attach the NEMA 23 silverpak motor 
to the motor mounting plate.  Next attach the drive pulley to the motor shaft.    
Sub assembly three, slider  
 
Attach the 27.875‖ bars to the 7.968‖ bars using the double anchor fasteners.  
Before these bars are fully attached to form the square frame make sure to slide two 
corner bracket assemblies onto each 7.968‖ bar. Also make sure to slide the U shaped 
support assembly onto the 7.968‖ bars before securing them to the 27.875‖ bars.  To the 
7.968‖ bars with the small corner brackets and screws provided.  
Now slide the slider assemble onto the upside down outside frame.  Now slide the 
linear bearings onto the outside frame.  Make sure they are aligned properly.  Attach the 
linear bearings to the ends of the 27.875‖ bars with the provided screws.  You may need 
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to use washer to achieve the desired fit.  Also make sure to attach the corner gusset 
supports between the 27.875‖ bars and the linear bearings.  The linear bearing slider 
assemble should be able to move vertically with ease.  Now you can attach the mounting 
bearings to the top of both the U shaped support assemblies.  Make sure to slide two 
80/20 nuts onto both vertical sides of one of the U shaped supports.  Make sure that the 
nuts are facing the outside of the frame.  Now you can attach the 17 mounting plate to the 
U shaped support.   
Now you can drill approximately a 1inch deep size 9 drill hole into the center end 
of the thread screw. Next take a ¼ inch flat end mill and remove the thread on the center 
line of the thread screw ½ inch from the end of the drilled thread screw.  Next drill a hole 
onto the flatten part of the thread screw with a #36 drill bit.  Drill the whole until you go 
into the horizontal hole which is already drilled.  Next tap the hole with a 6-32 tap.  Now 
you can friction fit the motor shaft onto the thread screw and tight the 6-32 ¼ inch set 
screw.   
Now you can take the motor and thread screw assembly and place the thread 
screw through one mounting bearing then thread the nut and pass the thread screw 
through the second mounting bearing.  Next secure the motor to the motor mount using 
the provided M3 screws.   
    
 Putting it together 
 Once this is on you can then attach the two 28.5‖ and two 5.5‖ beams with the 
double anchor fasteners.  The bottom of these beams should be attached 2‖ from the 
bottom of Sub assembly three.  Make sure that on the underside of the 28.5 inch beams 
you slide in two 80/20 ¼-20 nuts.  Once this rectangle is assembled you can attach the 
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base supports with the ½ inch ¼-20 screws.  Now you can drop base plate 2 into place.  
Once this is completed you can place the remaining pieces of plastic into their locations.  
Make sure that the base plate is positioned correctly by placing the end with the 24-well 
plate cut out on the right hand side the side with the smaller stepper motor by it.  Now 
Sub assembly one, roller cart can be placed in its location on the middle of Sub assembly 
two, slider.  Slide the cart until the nut bracket it touching the nut.  Now connect the nut 
to the nut bracket with the provided ¼-20 screws.     
You have now completed assembly of the frame.  Now you can attach the pulley 
string to the device.  The final step is to attach the wiring to the motors and plug it in.    
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APPENDIX 2: CAD Drawing of Final Design  
 
Whole Assembly 
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Base Plate 2 part #1 
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Beam 28.5 part #2 
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Beam 5.5 inch part #3 
 
 
Beam 15 inch part #4 
Please see 80/20 catalogue for dimensions of Aluminum T-Slotted Framing System 1010 
with an overall length of 15 inches.   
Beam 27.875 part #5 
Please see 80/20 catalogue for dimensions of Aluminum T-Slotted Framing System 1010 
with an overall length of 27.875 inches.   
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24 well plate part #6 
BD Falcon™ HTS 24-Multiwell Insert System and 
Cell Culture Insert Companion Plates 
 
Effective Diameter of Membranes 6.5 mm 
Effective Growth Area of Membrane 0.3 cm2 
Distance from Membrane to Bottom of Well 2.0 mm 
Insert Height 18.14 mm 
Suggested Media Volume in Insert 300-500 µl 
Suggested Media in Feeder Tray 30-40 ml 
Suggested Media Volume in Well 1000-1400 µl 
Effective Growth Area in 24-well Plate 2.0 cm2 
Pore Density: 1 µm insert 1.6 x 106 pores/cm2 
Pore Density: 3 µm insert 8.0 x 105 pores/cm2 
Pore Density: 8 µm insert 1.0 x 105 pores/cm2 
 
Plate Indexing Dimensions 
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Corner Bracket part #7 
Please see 80/20 catalogue for dimensions of pat # 4136- 10 S 4 Hole Inside Corner 
Gusset Bracket 
Linear Bearing part #8 
Please see 80/20 catalogue for dimensions of part # 6715- 10 S Single Flange Linear 
Bearing 
Beam 7.968 inch part #9 
Please see 80/20 catalogue for dimensions of Aluminum T-Slotted Framing System 1010 
with an overall length of 7.968 inches.   
Wheel part #10 
Please see 80/20 catalogue for dimensions of part # 2281- 10 S Roller Wheel 
Beam 4 inch part #11 
Please see 80/20 catalogue for dimensions 
Beam 6.253 inch part #12 
Please see 80/20 catalogue for dimensions of Aluminum T-Slotted Framing System 1010 
with an overall length of 6.253 inches.   
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Collector insert 3 part #13 
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Pipette base holder part #14 
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Pipette top holder part #15 
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Pipette large part #16 
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23 Mounting Plate 
  
99 
 
17 Mounting Plate
  
Nut Bracket  
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Support 4 
  
Support 7.5
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Tip Remover
  
Pipette Cap 
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Appendix 3: Testing Procedure 
 
Experiment:  Testing Proof of Concept 
 
 
Materials: 
24 well plate with plated spheroids (10 days old) 
P1000 pipette and tips 
P200 pipette and tips 
20% FBS 1% P/S Media 
Trypsin 
10 eppendorf tubes 
 
Procedure: 
1) Using P1000 pipette, add  1 mL 20% FBS 1% P/S Media to an eppendorf tube 
2) Using the P1000 pipette,  add .187 mL trypsin to one well 
3) Let stand for 5 min 
4) Using a P200 pipette, remove free cells and media from the well and transfer into 
the eppendorf tube containing  1 mL of media (do not remove spheroid) 
5) Using the P200 pipette, add 20 µL 20% FBS 1% P/S Media to the spheroid 
6) Let stand for 1 min 
7) Using the P1000 pipette,  add .187 mL trypsin to the spheroid 
8) Let stand for 5 min  
9) Using a new P1000 pipette tip, add 1 mL 20% FBS 1%P/S Media to the well 
10) Triturate manually for 2 minutes 
11) Plate the cells on a slide and observe under a microscope for cell isolation 
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Appendix 4: Stepper Motor Programs 
 
Stepper motor program for 17C motor that is controlling the x direction: 
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APPENDIX 5: Automatic Trituration System Quote 
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